Table 3.
The number of positive subjects of tumor markers and the MLR model.
| Marker 1 | CP 2 (n = 14) | PC 3 | p-Value 4 | ||
|---|---|---|---|---|---|
| III (n = 6) | IVa (n = 12) | IVb (n = 21) | |||
| CEA | 3.46 ± 3.27 | 2.75 ± 1.46 | 7.25 ± 4.18 | 43.8 ± 101 | 0.0196 * |
| >5.0 ng/mL | 3 (21.4) | 0 (0.00) | 9 (75.0) | 10 (47.6) | |
| #MV 5 | 0 | 0 | 0 | 0 | |
| CA19-9 | 19.9 ± 21.3 | 2.90 × 102 ± 6.26 × 102 | 7.43 × 102 ± 9.98 × 102 | 6.25 × 103 ± 1.77 × 104 | 0.0016 *** |
| >37 U/mL | 2 (14.3) | 3 (50.0) | 12 (100.0) | 16 (76.2) | |
| #MV 5 | 0 | 0 | 0 | 0 | |
| DUPAN2 | 74.0 ± 86.7 | 6.17 × 102 ± 7.67 × 102 | 5.28 × 102 ± 6.52 × 102 | 9.98 × 102 ± 6.52 × 102 | 0.0008 *** |
| >150 U/mL | 2 (16.7) | 4 (66.7) | 6 (50.0) | 18 (90.0) | |
| #MV 5 | 2 | 0 | 0 | 1 | |
| SPAN1 | 16.2 ± 17.1 | 89.0 ± 1.58 × 102 | 3.63 × 102 ± 4.83 × 102 | 3.25 × 103 ± 8.44 × 103 | <0.0001 *** |
| >30 U/mL | 2 (18.2) | 3 (50.0) | 10 (83.3) | 19 (95.0) | |
| #MV 5 | 3 | 0 | 0 | 1 | |
| MLR | 0.334 ± 0.266 | 0.800 ± 0.299 | 0.633 ± 0.363 | 0.786 ± 0.268 | 0.002 *** |
| > 0.5533 | 2 (14.3) | 5 (83.3) | 7 (58.3) | 16 (76.2) | |
| #MV 5 | 0 | 0 | 0 | 0 | |
Note: Values for markers and MLR were mean ± standard deviations. 1 Marker indicates tumor marker or multiple logistic regression (MLR) with their thresholds. The (%) indicates the percentage of positive subjects. 2 CP and 3 PC indicate chronic pancreatitis patients and pancreatic cancer patients, respectively. 4 Kruskal–Wallis test. 5 #MV indicates the number of missing values (MV). CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; Span-1: s-pancreas-1 antigen; DUPAN-2: duke pancreatic monoclonal antigen type 2, *: p <0.05 ***: p < 0.001.